ALX2004 vs Becotatug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
ALX2004
Developed by ALX Oncology Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07085091 (registry estimate)
No aligned efficacy figure on record for this race.
Becotatug
Developed by Shanghai JMT-Bio
NCT06380348 · Phase 3 · not yet recruiting
This was a randomized, open-label Phase 3 trial with 398 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-24. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.
Next expected readout: March 2027 · NCT06380348 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) as assessed by Independent Review Center (IRC) per RECIST 1.1 (Up to approximately 35 months after the first participant is randomized): Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24). (met)
Result source: NCT06380348
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALX2004 | Becotatug |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT06319313 |
| OS, median | —Not reported | —Trial running · NCT06319313 |
| ORR | —Not reported | —Trial running · NCT06319313 |
| Duration of response, median | —Not reported | —Trial running · NCT06319313 |
PFS, median
- ALX2004
- —Not reported
- Becotatug
- —Trial running · NCT06319313
OS, median
- ALX2004
- —Not reported
- Becotatug
- —Trial running · NCT06319313
ORR
- ALX2004
- —Not reported
- Becotatug
- —Trial running · NCT06319313
Duration of response, median
- ALX2004
- —Not reported
- Becotatug
- —Trial running · NCT06319313
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALX2004: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALX2004's landscape · Becotatug's landscape